Home › Therapeutic areas › Oncology › Prostate Cancer

Prostate Cancer (22 companies)

Companies with an active program in Prostate Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ADCT ADC Therapeutics Oncology 1 Approved $172M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
AKTS Aktis Oncology Oncology 1 Phase 1 $910M 10
DRTS Alpha Tau Medical Oncology 1 Phase 2 $1.12B 6
APVO Aptevo Therapeutics Oncology 2 Phase 1 $1.6M 8
ARVN Arvinas NeurologyOncology Rare 2 Approved $447M 10
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $30.7M 8
CADL Candel Therapeutics Oncology 1 Phase 3 $424M 4
CHRS Coherus Oncology Oncology 1 Approved $74.0M 5
EIKN Eikon Therapeutics Oncology 3 Phase 2 $279M 13
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
JANX Janux Therapeutics Oncology 3 Phase 1 $655M 4
KAPA Kairos Pharma Oncology 2 Phase 2 $1.9M 12
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
OLMA Olema Pharmaceuticals Oncology 1 Phase 3 $633M 3
ORIC Oric Pharmaceuticals Oncology 1 Phase 3 $831M 5
TLX Telix Pharmaceuticals Oncology 9 Approved $3.01B 25
VIR Vir Biotechnology Infectious DiseaseOncology Rare 2 Phase 3 $1.58B 6
XNCR Xencor ImmunologyNeurology+1 Rare 2 Approved $2.59B 28
ZYME Zymeworks OncologyRespiratory 1 Approved $1.78B 12